- Home
- AJG vs BDX Comparison
AJG vs BDX Comparison
Compare AJG & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AJG | BDX |
|---|---|---|
| Founded | 1927 | 1897 |
| Country | United States | United States |
| Employees | 706000 | N/A |
| Industry | Specialty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.0B | 43.0B |
| IPO Year | 1995 | 1998 |
Fundamental Metrics
Financial Performance| Metric | AJG | BDX |
|---|---|---|
| Price | $250.34 | $183.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 13 |
| Target Price | ★ $274.60 | $186.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | 1.32% | ★ 2.89% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.41 | 1.59 |
| Revenue | $6,159,600,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $30.53 | N/A |
| Revenue Next Year | $9.13 | $3.02 |
| P/E Ratio | ★ $56.96 | $115.35 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $190.75 | $140.11 |
| 52 Week High | $313.55 | $213.08 |
Technical Indicators
Market Signals| Indicator | AJG | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 53.68 | 73.01 |
| Support Level | $238.67 | $163.44 |
| Resistance Level | $263.59 | $187.35 |
| Average True Range (ATR) | 8.28 | 3.99 |
| MACD | -1.01 | 1.03 |
| Stochastic Oscillator | 40.52 | 88.72 |
Price Performance
Historical ComparisonAbout AJG Arthur J. Gallagher & Co.
Founded in 1927 as a one-person agency, Gallagher's primary business is insurance brokerage, with a focus on serving middle-market companies. The company's risk management segment provides third-party claims adjustment to companies that choose to self-insure. Gallagher has about 72,000 employees and generates about a third of its revenue internationally, primarily in Australia, Canada, New Zealand, and the UK.
About BDX Becton Dickinson and Company
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.